Cynata Therapeutics Limited (51S) Stock Statistics & Valuation Metrics
Total Valuation
Cynata Therapeutics Limited has a market cap or net worth of EUR 2.39M. The enterprise value is EUR 2.43M.
- Market Cap
- EUR 2.39M
- Enterprise Value
- EUR 2.43M
Share Statistics
Cynata Therapeutics Limited has 334,749,760 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 334,749,760
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Cynata Therapeutics Limited’s return on equity (ROE) is 23.46 and return on invested capital (ROIC) is 2072.95%.
- Return on Equity (ROE)
- 23.46
- Return on Assets (ROA)
- -6.83
- Return on Invested Capital (ROIC)
- 2072.95%
- Return on Capital Employed (ROCE)
- 24.57
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- 1.26
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Cynata Therapeutics Limited is -0.36. Cynata Therapeutics Limited’s PEG ratio is -0.03.
- PE Ratio
- -0.36
- PS Ratio
- 0.00
- PB Ratio
- -8.45
- Price to FCF
- -0.51
- Price to Operating Cash Flow
- -0.49
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Cynata Therapeutics Limited had revenue of 1.71M and earned -9.25M in profits. Earnings per share was -0.04.
- Revenue
- 1.71M
- Gross Profit
- -260.31K
- Operating Income
- -9.68M
- Pretax Income
- -10.96M
- Net Income
- -9.25M
- EBITDA
- -9.42M
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was -6.74M and capital expenditures 0, giving a free cash flow of -6.74M billion.
- Operating Cash Flow
- -6.74M
- Free Cash Flow
- -6.74M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Cynata Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -276.67%
- Earnings Yield
- -388.56%
Stock Price Statistics
- Beta
- -1.29
- 52-Week Price Change
- 94.29%
- 50-Day Moving Average
- 0.17
- 200-Day Moving Average
- 0.17
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Cynata Therapeutics Limited upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Cynata Therapeutics Limited as a current ratio of 0.64, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.64
- Quick Ratio
- 0.64
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.10
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Cynata Therapeutics Limited has paid -1.71M in taxes.
- Income Tax
- -1.71M
- Effective Tax Rate
- 0.16
Enterprise Valuation
Cynata Therapeutics Limited EV to EBITDA ratio is -0.16, with an EV/FCF ratio of -0.23.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.16
- EV to Free Cash Flow
- -0.23
- EV to Operating Cash Flow
- -0.23
Balance Sheet
Cynata Therapeutics Limited has EUR 897.42K in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 897.42K billion.
- Cash & Marketable Securities
- EUR 897.42K
- Total Debt
- EUR 0.00
- Net Cash
- EUR 897.42K
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Cynata Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 14.11%
Scores
- Smart Score
- 8
- AI Score
- ―
